Molecular Biology of Neurodegenerative Diseases: Visions for the Future
- 1st Edition, Volume 168 - November 6, 2019
- Latest edition
- Editor: David B. Teplow
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 7 8 7 4 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 7 8 7 5 - 1
Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Volume 168 in the Progress in Molecular Biology and Translational Science series, provides the most topical… Read more
Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Volume 168 in the Progress in Molecular Biology and Translational Science series, provides the most topical, informative and exciting monographs available on a wide variety of research topics. The series includes in-depth knowledge on the molecular biological aspects of organismal physiology, with this release including chapters on Alzheimer's disease, Prion-like propagation of alpha-synuclein, What - if anything - can we learn about neurodegenerative diseases from yeast?, Mitochondrial rejuvenation and replacement as a novel strategy for treatment of age-related neurodegenerative diseases, Propagation and removal of cerebral amyloid angiopathy, and much more.
- Includes comprehensive coverage of molecular biology
- Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
- Contains contributions from renowned experts in the field
Scientists working actively in a field, including those at levels ranging from graduate student to senior investigator. New investigators to a field who wish to familiarize themselves with the latest work
Section I: TARGETTING AD
1. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings
Kaj Blennow and Henrik Zetterberg
2. Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis
Minako Hoshi
3. Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid β-protein
Ariel J. Kuhn and Jevgenij A. Raskatov
Section II: ETIOLOGY OF AD
4. In search of pathogenic amyloid β-peptide in familial Alzheimer's disease
Michael S. Wolfe
5. Biology of splicing in Alzheimer's disease research
Kenichi Nagata, Takashi Saito, Takaomi C. Saido and Takashi Morihara
6. Acquired cerebral amyloid angiopathy: An emerging concept
Masahito Yamada, Tsuyoshi Hamaguchi and Kenji Sakai
Section III: NEUROIMMUNOLOGY OF
AD7. Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease
Goran Šimić, Ena Španić, Lea Langer Horvat and Patrick R. Hof
8. Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease
Susan Westfall, Umar Iqbal, Maria Sebastian and Giulio Maria Pasinetti
9. Neuroimmune interactions in Alzheimer’s disease—New frontier with old challenges?
Stefan Prokop, Virginia M.Y. Lee and John Q. Trojanowski
Section IV: AD THERAPY
10. Alzheimer's therapy development: A few points to consider
Einar M. Sigurdsson
11. The next steps in curing Alzheimer's disease
Fred W. van Leeuwen
12. Future horizons in Alzheimer's disease research
Thomas Wisniewski and Eleanor Drummond
13. Why delay in effective treatment for Alzheimer's disease and related conditions
Khalid Iqbal, Fei Liu, ChengXin Gong, Chunling Dai and Wen Hu
14. Restoring synaptic function through multimodal therapeutics
Raul Loera-Valencia, Muhammad-Al-Mustafa Ismail, Per Nilsson and Bengt Winblad
15. Disease-modifying therapy for proteinopathies: Can the exception become the rule?
Gal Bitan
16. Combination therapy for Alzheimer’s disease and related dementias
Martin M. Bednar
Section V: ALPHA-SYNUCLEINOPATHIES
17. Can infections trigger alpha-synucleinopathies?
Christopher T. Tulisiak, Gabriela Mercado, Wouter Peelaerts, Lena Brundin and Patrik Brundin
18. Prion-like propagation of α-synuclein in neurodegenerative diseases
Airi Tarutani and Masato Hasegawa
Section VI: MODEL SYSTEMS
19. Yeast models of neurodegenerative diseases
Mick F. Tuite
- Edition: 1
- Latest edition
- Volume: 168
- Published: November 6, 2019
- Language: English
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.
Affiliations and expertise
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USARead Molecular Biology of Neurodegenerative Diseases: Visions for the Future on ScienceDirect